Literature DB >> 20558778

Defective nitric oxide production by alveolar macrophages during Pneumocystis pneumonia.

Mark E Lasbury1, Chung-Ping Liao, Chadi A Hage, Pamela J Durant, Dennis Tschang, Shao-Hung Wang, Chen Zhang, Chao-Hung Lee.   

Abstract

The effect of nitric oxide (NO) on Pneumocystis (Pc) organisms, the role of NO in the defense against infection with Pc, and the production of NO by alveolar macrophages (AMs) during Pneumocystis pneumonia (PCP) were investigated. The results indicate that NO was toxic to Pc organisms and inhibited their proliferation in culture. When the production of NO was inhibited by intraperitoneal injection of rats with the nitric oxide synthase inhibitor L-N(5)-(1-iminoethyl) ornithine, progression of Pc infection in immunocompetent rats was enhanced. Concentrations of NO in bronchoalveolar lavage fluids from immunosuppressed, Pc-infected rats and mice were greatly reduced, compared with those from uninfected animals, and AMs from these animals were defective in NO production. However, inducible nitric oxide synthase (iNOS) mRNA and protein concentrations were high in AMs from Pc-infected rats and mice. Immunoblot analysis showed that iNOS in AMs from Pc-infected rats existed primarily as a monomer, but the homo-dimerization of iNOS monomers was required for the production of NO. When iNOS dimerization cofactors, including calmodulin, were added to macrophage lysates, iNOS dimerization increased, whereas incubation of the same lysates with all cofactors except calmodulin did not rescue iNOS dimer formation. These data suggest that NO is important in the defense against Pc infection, but that the production of NO in AMs during PCP is defective because of the reduced dimerization of iNOS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558778      PMCID: PMC3095925          DOI: 10.1165/rcmb.2009-0367OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  44 in total

1.  Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery.

Authors:  Mark E Lasbury; Pamela J Durant; Marilyn S Bartlett; James W Smith; Chao-Hung Lee
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

2.  Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine.

Authors:  F Y Liew; Y Li; S Millott
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

3.  N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine.

Authors:  D J Stuehr; N S Kwon; C F Nathan; O W Griffith; P L Feldman; J Wiseman
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

4.  Effect of transcription factor GATA-2 on phagocytic activity of alveolar macrophages from Pneumocystis carinii-infected hosts.

Authors:  Mark E Lasbury; Xing Tang; Pamela J Durant; Chao-Hung Lee
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

5.  Murine macrophage activation by staphylococcal exotoxins.

Authors:  S D Fleming; J J Iandolo; S K Chapes
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

6.  Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor.

Authors:  R A Ezekowitz; D J Williams; H Koziel; M Y Armstrong; A Warner; F F Richards; R M Rose
Journal:  Nature       Date:  1991-05-09       Impact factor: 49.962

7.  Quantitative plating of Histoplasma capsulatum without addition of conditioned medium or siderophores.

Authors:  P L Worsham; W E Goldman
Journal:  J Med Vet Mycol       Date:  1988-06

8.  Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide.

Authors:  D J Stuehr; M A Marletta
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.

Authors:  A H Ding; C F Nathan; D J Stuehr
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

10.  The interaction in vitro of Pneumocystis carinii with macrophages and L-cells.

Authors:  H Masur; T C Jones
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307

View more
  6 in total

1.  Differential Macrophage Polarization from Pneumocystis in Immunocompetent and Immunosuppressed Hosts: Potential Adjunctive Therapy during Pneumonia.

Authors:  Vijayalakshmi Nandakumar; Deanne Hebrink; Paige Jenson; Theodore Kottom; Andrew H Limper
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

2.  Mechanisms of Action of Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia.

Authors:  Guang-Sheng Lei; Chen Zhang; Bi-Hua Cheng; Chao-Hung Lee
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Pneumocystis Pneumonia: Checkpoint Inhibition to the Rescue?

Authors:  Julian Better; Ulrich Matt
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

Review 4.  Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy.

Authors:  Ryan Ha; Yoav Keynan; Zulma Vanessa Rueda
Journal:  Front Cell Infect Microbiol       Date:  2022-09-07       Impact factor: 6.073

5.  All-trans retinoic acid in combination with primaquine clears pneumocystis infection.

Authors:  Guang-Sheng Lei; Chen Zhang; Shoujin Shao; Hsin-Wei Jung; Pamela J Durant; Chao-Hung Lee
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240

Review 6.  Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections.

Authors:  C M Leopold Wager; F L Wormley
Journal:  Mucosal Immunol       Date:  2014-07-30       Impact factor: 8.701

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.